PRP or PRF and topical exosome material can share one appointment, and the practitioner decides how. The published record supports three arrangements in principle: the two kept on separate visits, applied in sequence on the same day, or mixed into one preparation. Only side-by-side application on skin has a controlled trial behind it [1], and no controlled trial has tested exosome material mixed into PRP or PRF on skin.
This guide follows on from the site’s comparisons of exosomes and PRP and turns to the combination question. It sets out how PRF differs from PRP, what the one located head-to-head trial did, what the mixing literature contains, what “PRP exosomes” can mean, how each product is regulated, and what a practice records when both appear in one file.
Regulatory position
PRP preparation systems reach the US market through 510(k) clearance [16], and the FDA classification for product code ORG describes preparing PRP for mixing with bone graft [17]. The FDA stated in 2019 that there are currently no FDA-approved exosome products [18]. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats. Whether, how and in what order the two are combined are practitioner decisions this article does not make.
Understanding how PRF differs from PRP in preparation and release
PRP and PRF both start as the patient’s own blood spun in a centrifuge, and they part ways at the tube. Dohan Ehrenfest and colleagues proposed in 2009 that platelet concentrates fall into four families by their leukocyte and fibrin content, and observed that each preparation method leads to a different product with different biology [20].
PRP is usually drawn into an anticoagulant so that it stays liquid until it is used. Liquid PRF is spun briefly and slowly without anticoagulant: Miron and colleagues described in 2017 an injectable PRF prepared at 60 g for 3 minutes [7], and Davies and Miron noted in 2025 that PRF left in the syringe clots within 20 to 40 minutes [4]. Solid PRF is allowed to clot in the tube and is handled as a membrane or plug.
That fibrin changes the release profile. Kobayashi and colleagues compared PRP, PRF and advanced PRF from six donors in 2016 and reported higher growth factor release from PRP in the first hour, with PRF releasing continually over ten days and advanced PRF releasing the most in total [6]. Fawzy El-Sayed and Dörfer reviewed the same contrast in 2026, describing PRP as a short-lived burst and the PRF fibrin network as a scaffold that retains what it holds [8].
| Feature | PRP | PRF (liquid or solid) | Supplied exosome material |
|---|---|---|---|
| Source | Patient’s own blood | Patient’s own blood | Supplied material with a lot number |
| Anticoagulant | Usually yes | No | Not applicable |
| Physical form at use | Liquid | Liquid that clots within 20 to 40 minutes in the syringe (Davies 2025), or a clot or membrane | Thawed liquid held at 4°C and used within 24 hours (ExaVeyra handling instructions) |
| Release pattern reported in the laboratory | Early burst (Kobayashi 2016) | Steady release over about 10 days (Kobayashi 2016) | Depends on the product; no comparable release study located |
| US regulatory path | Preparation system cleared by 510(k) (Beitzel 2015) | Clearance record of the centrifuge and tubes used | No FDA-approved exosome product (FDA, 2019) |
On clinical outcomes the comparison is still thin. Qin and colleagues reviewed 20 facial studies with 514 patients in 2025, pooling PRP and PRF, and reported the strongest evidence of improvement for skin thickness and elasticity and the weakest for hydration, where no included study reported a significant improvement [3]. Davies and Miron reported in a 2025 review that only a few studies compared PRP with PRF directly and that all of them favored PRF; Miron founded a PRF company, which the review declares [4].
Exosomes vs PRP and PRF: the one head-to-head trial kept the products on separate halves of the face
Estupiñan, Ly and Goldberg published the one located head-to-head comparison in 2025. Fifteen adults with mild to moderate photoaging had three full-face radiofrequency microneedling sessions four weeks apart, with PRP applied to the right side and a topical adipose-derived exosome product to the left [1].
The authors concluded that both sides improved equally on wrinkling, dyschromia, erythema, texture and overall appearance, with the exosome side showing slightly greater improvement in wrinkling, erythema and texture in the full results, and that biopsies from ten participants showed increased collagen I and glycosaminoglycans without a significant difference between arms [1]. The PRP was prepared with a platelet-rich fibrin matrix system, and the study was supported in part by a research grant from the company that supplied the exosome product and the microneedling device [1].
For a practice reading it as a combination study, the design is the point. Each product went onto its own half of the face after the same device session, so the trial shows two surface applications on needled skin side by side and says nothing about the two together on the same skin [1].
The wider exosome evidence is early. Gaebe and colleagues reviewed 16 facial vesicle studies with 503 participants in 2026 and reported improvement in at least one skin-quality outcome in most of them and no serious adverse events, while rating risk of bias as moderate to critical for most effectiveness outcomes and certainty as low or very low [2].
Exosomes mixed with PRP: no controlled trial has tested the mixture on skin
Searches of PubMed and ClinicalTrials.gov, last run on 9 November 2026, located no controlled study in which exosome material was mixed into PRP or PRF and applied to skin. What exists sits beside that question, and each piece is worth reading for what it covers.
The closest human example comes from dentistry. Froum and colleagues reported in 2026 on 27 consecutive patients treated in one private practice, whose solid PRF membranes were hydrated in placenta-derived exosomes mixed with liquid PRF before a surgical root-coverage procedure, with a mean root coverage of 68 percent at six months [10]. The series had no control group, the authors called for controlled studies, and one author declared PRF intellectual property [10].
In aesthetics, Chernoff described in 2023 a topical emulsion in which placental exosome material was mixed in a syringe with a neurotoxin and a hyaluronic acid filler before application [11]. That series of 40 patients had no PRP or PRF in the mixture and no arm comparing the mixture with its parts [11].
The carrier idea itself appears in the PRF review literature. Miron and colleagues listed liquid PRF as a possible delivery vehicle for exosomes among its future applications in 2024 [9], and Fawzy El-Sayed and Dörfer reviewed PRF as a carrier for several agents in 2026 and named the absence of standardized loading protocols as a major challenge [8]. ClinicalTrials.gov lists vesicle-enriched PRP studies outside aesthetics, among them a laboratory study of gum fibroblasts, NCT07855822, that had not begun recruiting as of 9 November 2026 [12]; none located tests a mixture on facial skin.
Questions a mixture raises that no study has measured
Whether citrate anticoagulant or a forming fibrin clot changes the stability, release or concentration of added vesicles is unmeasured. So is how far mixing dilutes the exosome material relative to its documented format. A practice that mixes is working beyond the published data, and its notes are the only record of what went into the syringe.
Exosomes after PRP: layered and separate-session approaches keep each record intact
Layering applies one product and then the other to the same area in the same appointment, so that exosome material after PRP, or PRP after exosome material, are both layered orders. No located study has compared those orders, or compared layering with separate visits, so the sequence remains the practitioner’s call.
Layering and separate sessions share a practical advantage. Each product keeps its own identity in the chart: the PRP or PRF by its device, tubes and spin, and the exosome material by its lot number, certificate of analysis and cold-chain record. If a reaction or a question arises later, each step can be traced on its own.
Where either product is applied after microneedling, the FDA’s microneedling page is relevant to both. It states that microneedling devices are not approved for delivery of cosmetics, topical medications, drugs or blood products such as platelet-rich plasma into the skin, and that the risks of combining the devices with other products are not known [19].
PRP exosomes before and after: two different products share the name
Searches for PRP exosomes before and after photographs mix two different things. One is supplied exosome material used alongside PRP, the subject of everything above. The other is vesicles released from the patient’s own platelets, which PRP contains naturally and which some devices aim to increase [13].
Gupta and colleagues reviewed PRP-derived vesicles in 2025 and described PRP as an abundant source of them, with mostly preclinical data, scarce information on skin rejuvenation and hair growth, and isolation, activation and delivery methods not yet optimized [13]. Vilà Rodríguez and colleagues reported a 2026 pilot of vesicles released from preconditioned PRP in 11 women, 9 of whom completed the study; two of the three authors work for the device maker [15].
Wanitphakdeedecha and colleagues randomized the two sides of the face in 28 volunteers in 2026 to standard PRP or PRP preconditioned with light and warmth, using a device preset its maker calls an exosome program [14]. They reported greater improvement in periorbital fine lines, folds and wrinkles on the preconditioned side and similar results for pigmentation, redness and firmness; the abstract reports no vesicle measurement, the trial was registered retrospectively, and the device maker provided medical writing assistance [14].
For a reader comparing before and after images, the useful questions are which of the two meanings the clinic intends, what product or preconditioning step was used, how many sessions separated the photographs, and whether lighting and position were standardized. Where the studies above publish photographs, each carries the design limits noted.
Regulatory status differs for each side of a combined session
Beitzel and colleagues reported in 2015 that PRP preparation systems reach the US market through 510(k) clearance, that nearly all were cleared for preparing PRP to mix with bone graft to improve handling, and that other uses are off label [16]. They quoted the FDA’s biologics center as expecting clinicians to be well informed about the product and to maintain records of its use and effects [16].
The FDA classification for product code ORG matches that account, defining the device as a separator for preparing autologous PRP from a small sample of peripheral blood for mixing with bone graft [17]. PRF is prepared with centrifuges and tubes, so the practice file holds the clearance record for whatever equipment it uses.
Exosome material sits under a separate framework. The FDA stated in its 2019 notification, still posted as of 9 November 2026, that there are currently no FDA-approved exosome products and that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products, and it directed adverse event reports to MedWatch [18]. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats.
| Item | PRP or PRF preparation | Topical exosome material |
|---|---|---|
| What the FDA reviewed | The preparation device, through 510(k) | No FDA-approved exosome product (FDA, 2019) |
| What the clearance or statement describes | Preparing PRP for mixing with bone graft (product code ORG) | Exosomes used in humans to address diseases and conditions are regulated as drugs and biological products |
| Identity in the chart | Device, tube lot, spin settings, draw volume and time to use | Product name, lot number, certificate of analysis and cold-chain record |
| Adverse event route | MedWatch, naming the device | MedWatch, naming the product and lot |
Understanding what the evidence does not yet show
The combination question is open in specific, answerable ways. Each gap below is a study a practice or an investigator could design.
- No controlled human study has applied exosome material mixed into PRP or PRF to skin; the located mixtures are a dental case series [10] and a topical emulsion without platelet concentrate [11].
- No study has compared exosome material after PRP with PRP after exosome material, or either with separate visits.
- The one located head-to-head trial enrolled 15 adults, kept the products on separate halves of the face, and was supported in part by the company that supplied the exosome product and device [1].
- Release data for PRP and PRF come from laboratory studies [6, 7], which do not measure what happens on skin.
- Head-to-head PRP and PRF trials in aesthetics are few, and the review that found all of them favoring PRF was written by authors affiliated with a PRF education company, one of whom founded a PRF company [4].
- Reviewers in dermatologic surgery stated in 2024 that the absence of expert consensus and standardized protocols, and varying outcomes, hold back wider acceptance of PRP and PRF in cosmetic dermatology [5].
- Studies of vesicles released from the patient’s own PRP are small and have device-maker involvement [14, 15].
- Gaebe and colleagues rated the certainty of facial vesicle evidence as low or very low in 2026 [2], and exosome materials differ by source, isolation and concentration.
What to ask and document when PRP or PRF and exosome material share a session
A record that captures each product separately lets a practice compare its own sessions with the studies above and answer later questions from one file. The fields below follow the studies and agency sources cited in this guide [16, 18, 19].
- Whether the session kept the products separate, layered them, or mixed them, and the practitioner’s reason
- For PRP or PRF: the centrifuge and tube by name, lot and FDA clearance, the anticoagulant if any, spin speed and time, draw volume and the time from draw to use
- For the exosome material: product name and source, lot number, certificate of analysis, characterization panel and cold-chain record from receipt to thaw
- For any mixture: the volumes of each component, the vessel, and the time between mixing and application
- Any device session by model and clearance, with depth and settings, and the order of every step
- Standardized photographs at baseline and follow-up, with the same lighting and position
- Any adverse event, with the device and the exosome lot, reported to the FDA through MedWatch
Patients can bring the same list to a consultation and ask their provider which arrangement they use and why. The answer belongs to the practitioner, and a clear record is what lets that answer improve as the evidence grows.
Documented supply supports combined sessions
Combined sessions are a natural next step for practices that already offer PRP or PRF, and careful records will shape the studies that settle the open questions. ExaVeyra exosome material ships frozen from the manufacturing facility in every format. Every vial carries its lot number, and a certificate of analysis is generated for every lot and is available on request together with the characterization panel and cold-chain records; every certificate reports serological testing for pathogens, and miRNA characterization data is available on request. ExaVeyra PRP kits are coming soon, so both sides of a combined session will be able to come from one documented supplier.
Anyone can ask the scientific team a question or apply without an NPI, and NPI verification unlocks the practitioner portal, exclusive resources and pricing, so a practice planning combined sessions can apply for a verified account today.
Aviso Educativo: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
Referencias
- 1.Estupiñan B, Ly K, Goldberg DJ. Adipose Mesenchymal Stem Cell-Derived Exosomes Versus Platelet-Rich Plasma Treatment for Photoaged Facial Skin: An Investigator-Blinded, Split-Face, Non-Inferiority Trial. J Cosmet Dermatol. 2025;24(5):e70208. PMID 40414798. PMC12104007. doi:10.1111/jocd.70208Investigator-blinded split-face trial (New Jersey, USA); 15 adults with mild to moderate photoaging as the study subjects enrolled and one discontinued after withdrawing consent for biopsies; three radiofrequency microneedling sessions 4 weeks apart, with PRP (prepared using a platelet-rich fibrin matrix system) applied to one side and a topical adipose-derived exosome product to the other; biopsies in 10. Carries in this article: the only located head-to-head comparison; the abstract concludes that both sides improved equally, the results section reports slightly greater improvement in wrinkling, erythema and texture on the exosome side, biopsies in 10 participants showed no significant histological difference between arms, and each product was applied to its own half of the face. Funding: supported in part by a research grant from the company that supplied the exosome product and the microneedling device used; the authors declared no conflicts of interest.
- 2.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk-of-bias and GRADE assessment, searches January 2000 to June 2025; 16 studies, 503 participants. Carries in this article: the authors reported improvement in at least one skin-quality outcome in most studies and no serious adverse events, rated risk of bias moderate to critical and certainty low or very low, and concluded that short follow-up and inconsistent outcome assessment preclude definitive conclusions. Disclosure: academic authors (Canada); no COI statement in the PubMed record.
- 3.Qin N, Kochheiser M, Akosman I, Dugue D, Raghunandan A, Pavuluri C, et al. Systematic Review of Platelet-Rich Plasma and Platelet-Rich Fibrin in Facial Rejuvenation. Ann Plast Surg. 2025;94(4S Suppl 2):S376-S389. PMID 40167104. doi:10.1097/SAP.0000000000004267Systematic review (Weill Cornell); 20 studies, 514 patients, PRP or PRF as monotherapy, studies published after 2010. Carries in this article: the authors identified skin thickness and elasticity as the parameters with the strongest evidence of improvement and hydration as the weakest, with no included hydration study reporting significant improvement and no serious adverse events in any included study. Disclosure: conflicts of interest and funding declared as none.
- 4.Davies C, Miron RJ. Autolougous [sic] platelet concentrates in esthetic medicine. Periodontol 2000. 2025;97(1):363-419. PMID 39086171. PMC11808453. doi:10.1111/prd.12582Narrative review built on a systematic PubMed search for randomized trials to October 2023; 96 articles on PRP, PRGF and PRF in facial esthetics and dermatology. Carries in this article: the authors reported that only a few studies compared PRP with PRF directly, all favoring PRF, named small samples and unstandardized assessment as limits, and noted that PRF left in the syringe clots within 20 to 40 minutes. Disclosure: R.J. Miron is the founder of a PRF company (declared), and both authors list a PRF education affiliation.
- 5.Proffer SL, Wyles SP, Hausauer AK. Update on Platelet-Rich Plasma and Platelet-Rich Fibrin for Dermatologic Surgery: Addressing Knowns and Unknowns. Dermatol Surg. 2024;50(11S):S149-S159. PMID 39480038. doi:10.1097/DSS.0000000000004421Literature review in the American Society for Dermatologic Surgery journal, weighted to level 1A to 2A evidence from 2022 to 2024. Carries in this article: the authors stated that the absence of expert consensus and standardized protocols, and varying outcomes, limit acceptance of PRP and PRF in cosmetic dermatology. Disclosure: no COI statement in the PubMed record.
- 6.Kobayashi E, Flückiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B, et al. Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Investig. 2016;20(9):2353-2360. PMID 26809431. doi:10.1007/s00784-016-1719-1In vitro release study; 18 samples from 6 donors, growth factors measured by ELISA from 15 minutes to 10 days. Carries in this article: the authors reported higher early release from PRP and continual, steady release from PRF over 10 days, with the highest total release from advanced PRF. Disclosure: no COI statement in the PubMed record; senior author R.J. Miron later declared PRF intellectual property.
- 7.Miron RJ, Fujioka-Kobayashi M, Hernandez M, Kandalam U, Zhang Y, Ghanaati S, et al. Injectable platelet rich fibrin (i-PRF): opportunities in regenerative dentistry? Clin Oral Investig. 2017;21(8):2619-2627. PMID 28154995. doi:10.1007/s00784-017-2063-9In vitro study; standard PRP against a liquid PRF spun at 60 g for 3 minutes without anticoagulant, 8 donor samples, release to 10 days and fibroblast assays. Carries in this article: the definition of liquid PRF as an anticoagulant-free preparation, and the reported pattern of higher early release from PRP and higher 10-day totals of several growth factors from i-PRF. Disclosure: no COI statement in the PubMed record; R.J. Miron and J. Choukroun later declared PRF interests.
- 8.Fawzy El-Sayed KM, Dörfer CE. Platelet-Rich Fibrins as Local Drug-Delivery Carriers. J Periodontal Res. 2026. Published online ahead of print. PMID 42089193. doi:10.1111/jre.70114Narrative review (Egypt and Germany) of autologous platelet concentrates loaded with antibiotics, antifungals, vitamins, exosomes and other agents. Carries in this article: the authors described PRP release as a short-lived burst and the PRF fibrin network as a scaffold that retains growth factors and loaded agents, and named the absence of standardized loading protocols as a major challenge. Disclosure: no COI statement in the PubMed record.
- 9.Miron RJ, Gruber R, Farshidfar N, Sculean A, Zhang Y. Ten years of injectable platelet-rich fibrin. Periodontol 2000. 2024;94(1):92-113. PMID 38037213. doi:10.1111/prd.12538Narrative review of liquid PRF (i-PRF) since 2014. Carries in this article: the authors listed use of i-PRF as a carrier for small biomolecules, exosomes among them, as a future application, which places mixing in the forward-looking part of the PRF literature. Disclosure: no COI statement in the PubMed record; R.J. Miron has elsewhere declared PRF intellectual property.
- 10.Froum S, Estrin NE, Ahmad P, Farshidfar N, Miron RJ. The Feasibility of Exosome-Enriched Platelet-rich Fibrin (PRF) for the Treatment of Gingival Recessions: A Case Series of 27 Patients. Oral Health Prev Dent. 2026;24:51-60. PMID 41603870. PMC12852986. doi:10.3290/j.ohpd.c_2394Single-arm retrospective case series from one private dental practice (USA); 27 patients, 125 teeth, solid PRF from horizontal centrifugation hydrated in placenta-derived exosomes mixed 1:1 with liquid PRF before surgical application in a root-coverage procedure, 6-month follow-up. Carries in this article: the closest located human use of exosomes mixed into a platelet concentrate, outside skin and without a control group; the authors reported a mean root coverage of 68 percent and called for controlled studies. Disclosure: R.J. Miron declared PRF intellectual property and a PRF research company.
- 11.Chernoff G. Combining topical dermal infused exosomes with injected calcium hydroxylapatite for enhanced tissue biostimulation. J Cosmet Dermatol. 2023;22 Suppl 1:15-27. PMID 36988469. doi:10.1111/jocd.15695Uncontrolled IRB-approved clinical series (USA); 40 patients in five groups, 3-D photographic analysis at 15 and 30 days. Carries in this article: a published example of placental exosome material mixed in a syringe with other agents (a neurotoxin and a hyaluronic acid filler) into a topical emulsion, with no PRP or PRF in the mixture and no arm testing the mixture against its parts. Disclosure: single author; no COI statement in the PubMed record.
- 12.Inonu University. Effects of Standard PRP and Extracellular Vesicle-Enriched PRP on Human Gingival Fibroblasts. ClinicalTrials.gov NCT07855822. First posted October 2, 2026; status not yet recruiting (record last updated October 7, 2026), estimated start October 11, 2026. clinicaltrials.gov/study/NCT07855822Registered prospective in vitro study; 6 healthy volunteers planned, each giving one blood sample, comparing standard PRP with PRP enriched in its own platelet-derived vesicles on gingival fibroblasts. Carries in this article: an example of a registered laboratory comparison of a vesicle-enriched PRP, still not yet recruiting when verified on ClinicalTrials.gov, 9 November 2026.
- 13.Gupta AK, Wang T, Rapaport JA, Talukder M. Therapeutic Potential of Extracellular Vesicles (Exosomes) Derived From Platelet-Rich Plasma: A Literature Review. J Cosmet Dermatol. 2025;24(2):e16709. PMID 39618056. PMC11845942. doi:10.1111/jocd.16709Literature review (Embase, Web of Science and ClinicalTrials.gov, June 2024). Carries in this article: the authors described PRP as an abundant source of extracellular vesicles, reported mostly preclinical data and scarce information on hair growth and skin rejuvenation, and stated that isolation, activation and delivery methods have not been optimized. Disclosure: the authors declared no conflicts of interest.
- 14.Wanitphakdeedecha R, Ollero MPGCR, Bhorntarakcharoen W, Sittiwanaruk S, Phokai W, Woramongkol T, et al. Efficacy and safety of photothermal biomodulated platelet-rich plasma versus standard platelet-rich plasma for facial rejuvenation: a prospective split-face randomized study. Sci Rep. 2026;16(1):25017. PMID 42225690. PMC13462578. doi:10.1038/s41598-026-54310-9Prospective randomized split-face study (Thailand); 28 volunteers, three monthly sessions, follow-up to 6 months; one side received standard PRP and the other PRP preconditioned in a device preset the maker names an exosome program (467 nm light, 37 degrees C, 10 minutes). Carries in this article: the authors reported greater periorbital fine line, fold and wrinkle improvement on the preconditioned side and similar pigmentation, redness and biomechanical results; the abstract reports no vesicle measurement. Disclosure: the authors declared no competing interests; medical writing assistance was provided by the device maker, and the trial was registered retrospectively (TCTR20251020002).
- 15.Vilà Rodríguez D, Cordero L, Pinto H. Facial rejuvenation with autologous exosomes released from preconditioned platelet-rich plasma using the meta cell technology system: A pilot study. Dermatol Online J. 2026;32(2). PMID 42522478. doi:10.25251/b5kf0v44Single-center pilot study (Spain), described by the authors as randomized and controlled; 11 women enrolled and 9 completed the study. Carries in this article: an example of vesicles released from the patient’s own preconditioned PRP, the second meaning of PRP exosomes; the authors reported ultrasound and patient-rated changes one month after the last session. Disclosure: two of the three authors are employees of the device maker.
- 16.Beitzel K, Allen D, Apostolakos J, Russell RP, McCarthy MB, Gallo GJ, et al. US definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine. J Knee Surg. 2015;28(1):29-34. PMID 25268794. doi:10.1055/s-0034-1390030Regulatory review (USA and Germany). Carries in this article: the authors reported that PRP preparation systems reach the market through 510(k) clearance, that nearly all were cleared for mixing with bone graft to improve handling, that other uses are off label, and quoted the CBER expectation that clinicians maintain records of a product’s use and effects. Disclosure: no COI statement in the PubMed record.
- 17.U.S. Food and Drug Administration. Product Classification database, product code ORG: platelet and plasma separator for bone graft handling; 21 CFR 864.9245, Class II, 510(k). Verified through the openFDA device classification API, 9 November 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?id=ORGFDA device classification entry. Carries in this article: the classification definition reads preparation of autologous platelet rich plasma from a small sample of peripheral blood for mixing with bone graft to improve handling characteristics, the basis for saying a cleared PRP system is cleared to prepare PRP and names no aesthetic use.
- 18.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the agency statement that there are currently no FDA-approved exosome products and that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products, and its direction to report adverse events through MedWatch.
- 19.U.S. Food and Drug Administration. Microneedling Devices. Content current as of 10/15/2025; verified 9 November 2026. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devicesAgency device information page (CDRH). Carries in this article: the page states that microneedling devices are not approved for delivery of cosmetics, topical medications, drugs or blood products, naming platelet-rich plasma, into the skin, and that the risks of combining the devices with other products are not known.
- 20.Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27(3):158-67. PMID 19187989. doi:10.1016/j.tibtech.2008.11.009Narrative review and classification proposal (Sweden). Carries in this article: the four families of platelet concentrates sorted by leukocyte and fibrin content, the authors’ basis for separating PRP from PRF, and their observation that each preparation method yields a different product. Disclosure: no COI statement in the PubMed record.